Catalog No.: PC-45774Not For Human Use, Lab Use Only.
BML-284 (AMBMP) is a potent selective, and cell-permeable canonical Wnt/β-catenin pathway activator with EC50 of 0.7 uM (induces beta-catenin- and TCF-dependent transcriptional activity).
BML-284 (AMBMP) is a potent selective, and cell-permeable canonical Wnt/β-catenin pathway activator with EC50 of 0.7 uM (induces beta-catenin- and TCF-dependent transcriptional activity).
BML-284 induces the rapid phosphorylation of NFκB p65 at Ser536 and abrogates total IκB, accompanied by a subsequent increase in pro-inflammatory cytokine production (TNF, IL-6, IL-12 p40) in otherwise naive monocytes.
AMBMP treatment activates CaMKII and metabolically reprograms skeletal muscle toward a slow muscle phenotype.
1. Liu J, et al. Angew Chem Int Ed Engl. 2005 Mar 18;44(13):1987-90.
2. Denicol AC, et al. Sci Rep. 2013;3:1266. doi: 10.1038/srep01266.
3. Wang H, et al. Inflamm Res. 2016 Jan;65(1):61-9.
4. Liu J, et al. Cell Rep Med. 2020 Oct 20;1(7):100122.
